Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Keratosis, Actinic 4 Neoplasms 2 Keratosis 2 Stomach Neoplasms 1 Precancerous Conditions 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Carcinoma 1 Breast Neoplasms 1 Bone-Metastatic, Castration-Resistant Prostate Cancer 1

Interventions

Rituximab 63 Cyclophosphamide 37 Brentuximab Vedotin 22 Bendamustine Hydrochloride 22 pembrolizumab 20 fludarabine 20 Gemcitabine 20 Doxorubicin 20 Prednisone 19 ibrutinib 17 Vincristine 16 obinutuzumab 14 Lenalidomide 13 Nivolumab 10 Rifampin 8 parsaclisib 7 duvelisib 7 atezolizumab 7 Vorinostat 7 Dexamethasone 7 Azacitidine 7 spartalizumab 6 loncastuximab tesirine 6 MLN 8237 6 venetoclax 5 ixazomib 5 glofitamab 5 fludarabine phosphate 5 durvalumab 5 acalabrutinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphoma × tirbanibulin × Clear all

NCT00658970 2011-06-08

Evaluation of KX2-391 in Patients With Advanced Malignancies

Athenex, Inc.

Phase 1 Completed

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡